These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15577450)

  • 21. SBRT in Localized Renal Carcinoma: A Review of the Literature.
    DE LA Pinta C; Latorre RG; Fuentes R
    Anticancer Res; 2022 Feb; 42(2):667-674. PubMed ID: 35093865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
    Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
    Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis.
    Huang RS; Chow R; Chopade P; Mihalache A; Hasan A; Boldt G; Glicksman R; Simone CB; Lock M; Raman S
    Radiother Oncol; 2024 May; 194():110216. PubMed ID: 38462092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases.
    Scorsetti M; Facoetti A; Navarria P; Bignardi M; De Santis M; Ninone SA; Lattuada P; Urso G; Vigorito S; Mancosu P; Del Vecchio M
    Anticancer Res; 2009 Oct; 29(10):4259-63. PubMed ID: 19846983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery.
    Chang EL; Selek U; Hassenbusch SJ; Maor MH; Allen PK; Mahajan A; Sawaya R; Woo SY
    Neurosurgery; 2005 May; 56(5):936-45; discussion 936-45. PubMed ID: 15854241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calvarial and skull base metastases: expanding the clinical utility of Gamma Knife surgery.
    Kotecha R; Angelov L; Barnett GH; Reddy CA; Suh JH; Murphy ES; Neyman G; Chao ST
    J Neurosurg; 2014 Dec; 121 Suppl():91-101. PubMed ID: 25434942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A systematic review of radiotherapy for primary renal cell carcinoma].
    Gladilina IA; Shabanov MA; Kushlinskii NE; Bliganov PI; Sergeev AN
    Urologiia; 2022 Mar; (1):96-101. PubMed ID: 35274868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience.
    Nomiya T; Tsuji H; Hirasawa N; Kato H; Kamada T; Mizoe J; Kishi H; Kamura K; Wada H; Nemoto K; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):828-33. PubMed ID: 18374507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
    Franzese C; Franceschini D; Di Brina L; D'Agostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
    J Urol; 2019 Jan; 201(1):70-76. PubMed ID: 30179619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W
    J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
    Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
    J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
    Müller AC; van Oorschot B; Micke O; Guckenberger M
    Strahlenther Onkol; 2018 Jan; 194(1):1-8. PubMed ID: 28819766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy.
    Poon I; Pintilie M; Potvin M; McGowan T
    Can J Urol; 2004 Feb; 11(1):2125-32. PubMed ID: 15003151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT.
    Hou JZ; Zeng ZC; Wang BL; Yang P; Zhang JY; Mo HF
    Jpn J Clin Oncol; 2016 Apr; 46(4):357-62. PubMed ID: 26802166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
    Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
    BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma.
    Goyal LK; Suh JH; Reddy CA; Barnett GH
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1007-12. PubMed ID: 10863072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
    Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
    Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma.
    Rades D; Huttenlocher S; Gebauer N; Hornung D; Trang NT; Khoa MT; Schild SE
    Anticancer Res; 2015 Jun; 35(6):3571-4. PubMed ID: 26026128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.